Presentation is loading. Please wait.

Presentation is loading. Please wait.

Biology of Blood and Marrow Transplantation

Published byEmerald Cook Modified over 5 years ago

Similar presentations

Presentation on theme: "Biology of Blood and Marrow Transplantation"— Presentation transcript:

1 Biology of Blood and Marrow Transplantation
Reduction in Systolic Hypertension in Children Undergoing Hematopoietic Stem Cell Transplantation  Adam S. Nelson, MBBS, Michelle Lewyckyj, MSN, RNIII, CPN, CPON, BMTCN, Laura Flesch, MSN, RN, CRNP, Kathleen Novak, RNII, MSN, CPN, Kathleen Marie Demmel, BSN, RN, MHA, Ashley Teusink, PharmD, MBA, BCPS, Sonata Jodele, MD, Stella M. Davies, MBBS, PhD, Christopher E. Dandoy, MD, MSc  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, (March 2016) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Figure 2 Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Biology of Blood and Marrow Transplantation"

Similar presentations

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
BK Viremia Precedes Hemorrhagic Cystitis in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation  Benjamin L. Laskin, Michelle Denburg,

BK Viremia Precedes Hemorrhagic Cystitis in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation  Benjamin L. Laskin, Michelle Denburg,
Phase 1 Study of Maraviroc As Acute Graft-Versus-Host Disease Prophylaxis in Pediatrics  Pooja Khandelwal, MD, Tsuyoshi Fukuda, PhD, Ashley Teusink, PharmD,

Phase 1 Study of Maraviroc As Acute Graft-Versus-Host Disease Prophylaxis in Pediatrics  Pooja Khandelwal, MD, Tsuyoshi Fukuda, PhD, Ashley Teusink, PharmD,
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Kristen M. Coleman, RN, BSN, Stella M

Kristen M. Coleman, RN, BSN, Stella M
Using A3 Methodology to Identify the Root Cause of a Chemotherapy Error in a Hematopoietic Stem Cell Transplant Patient  Kathlene DeGregory, PharmD, BCOP,

Using A3 Methodology to Identify the Root Cause of a Chemotherapy Error in a Hematopoietic Stem Cell Transplant Patient  Kathlene DeGregory, PharmD, BCOP,
Vitamin A Deficiency Is Associated with Increased Risk of Acute Graft Versus Host Disease in Children  Dana T. Lounder, MD, Sonata Jodele, MD, Pooja Khandelwal,

Vitamin A Deficiency Is Associated with Increased Risk of Acute Graft Versus Host Disease in Children  Dana T. Lounder, MD, Sonata Jodele, MD, Pooja Khandelwal,
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation 

Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation 
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA) 

Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA) 
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.

Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.
Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,

Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,
Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.
Access to Hematopoietic Cell Transplantation in the United States

Access to Hematopoietic Cell Transplantation in the United States
CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.
Gregory Wallace, DO, Sonata Jodele, MD, Kasiani C

Gregory Wallace, DO, Sonata Jodele, MD, Kasiani C
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 
Pharmacogenetic Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplants  Ashley Teusink,

Pharmacogenetic Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplants  Ashley Teusink,

Similar presentations

Ads by Google